Candel Therapeutics (CADL) Accumulated Depreciation (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Accumulated Depreciation data on file, last reported at $3.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation rose 15.67% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 15.67% YoY), and the FY2025 full-year result was $3.6 million, up 15.67% from the prior year.
• Accumulated Depreciation improved to $3.6 million in Q4 2025, from $3.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $3.6 million in Q2 2025 to a low of $167000.0 in Q2 2021.
• A 5-year average of $1.9 million and a median of $1.8 million in 2023 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation jumped 383.51% in 2022 and rose 15.67% in 2025, its largest moves.
• Tracing CADL's Accumulated Depreciation over 5 years: stood at $352000.0 in 2021, then jumped by 220.74% to $1.1 million in 2022, then soared by 85.03% to $2.1 million in 2023, then surged by 47.25% to $3.1 million in 2024, then increased by 15.67% to $3.6 million in 2025.
• Business Quant data shows CADL's Accumulated Depreciation at $3.6 million in Q4 2025, $3.4 million in Q3 2025, and $3.6 million in Q2 2025.